Abstract
Conclusive evidence demonstrates that the sympathetic nervous system activation is a hallmark of congestive heart failure. This has been shown via a variety of biochemical, neurophysiological, and neuroimaging approaches for studying human sympathetic neural function. The sympathetic activation appears to be an early phenomenon in the clinical course of the disease, closely related to its severity and potentiated by the concomitant presence of other comorbidities, such as obesity, diabetes mellitus, metabolic syndrome, hypertension, and renal failure. The adrenergic overdrive in heart failure is associated with other sympathetic abnormalities, such as the downregulation of beta-adrenergic adrenoreceptors at cardiac level, and exerts unfavorable consequences on the cardiovascular system. These include the endothelial dysfunction, the development of left ventricular hypertrophy, the atherosclerosis development, as well as the generation of atrial and ventricular arrhythmias, and, at very extreme levels of sympathetic activation, the occurrence of microscopic myocardial necrosis. Given the close direct independent relationships detected in heart failure between sympathetic activation and mortality, the adrenergic overdrive has become a target of neuromodulatory therapeutic interventions, which include non-pharmacological, pharmacological, and device-based interventions. For some of these approaches (specifically bilateral renal nerves ablation and carotid baroreceptor stimulation), additional studies are needed to better define their impact on the clinical course of the disease.
Similar content being viewed by others
References
Willis T (1664-1964) The anatomy of the brain and nerves, 3rd edn. Feindel W (ed). McGill University Press, Montreal
Heymans CJF, Folkow B (1982) Vasomotor control and regulation of blood pressure. In: Fishman AP, Richards DW (eds) Circulation of the blood. Men and Ideas. American Physiological Society, Bethesda, pp 407–486
Von Euler US (1946) A specific sympathetic ergone in adrenergic nerve fibres (sympathin) and its relation to adrenaline and noradrenaline. Acta Physiol Scand 12:73–97
Von Euler US, Hellner S, Purkhold A (1954) Excretion of noradrenaline in the urine in hypertension. Scand J Clin Lab Invest 6:54–59
Grassi G, Esler M (1999) How to assess sympathetic activity in humans. J Hypertens 17:719–734
Goldstein DS, Chang PC, Eisenhofer G, Miletich R, Finn R, BacherJ (1990) Positron emission tomographic imaging of cardiac sympathetic innervation and function. Circulation 81:1606–1621
Hagbarth KE, Vallbo AB (1968) Pulse and respiratory grouping of sympathetic impulses in human muscle nerves. Acta Physiol Scand 74:96–106
Wallin BG, Delius W, Hagbarth KE (1973) Comparison of sympathetic nerve activity in normotensive and hypertensive subjects. Circ Res 33:9–21
Grassi G, Colombo M, Seravalle G, Spaziani D, Mancia G (1998) Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension 31:64–67
Grassi G, Seravalle G, Quarti-Trevano F, Dell’Oro R, Bolla G, Mancia G (2003) Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension 42:873–877
Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, Del Bo A, Sala C, Bolla GB, Pozzi M, Mancia G (1995) Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 92:3206–3211
Macefield V, Wallin BG, Vallbo AB (1994) The discharge behaviour of single vasoconstrictor motoneurones in human muscle nerves. J Physiol Lond 481:799–809
Lambert E, Straznicky N, Schlaich MP, Dawood T, Hotchkin E, Esler MD, Lambert GW (2007) Differing patterns of sympathoexcitation in normal weight and obesity-related hypertension. Hypertension 50:862–868
Seals DR, Esler MD (2000) Topical review: human ageing and the sympathoadrenal system. J Physiol (London) 528:407–417
Macefield VG, Rundqvist B, Bergmann-Sverrisdottir Y, Wallin BG, Elam M (1999) Firing properties of single muscle vasoconstrictor neurons in the sympathoexcitation associated with heart failure. Circulation 100:1708–1713
Vaddadi GL, Esler MD, Socratous F, Schlaich MP, Chopra R, Eikelis N, Lambert G, Trauer T, Lambert E (2011) Recurrent postural vasovagal syncope: sympathetic nervous system phenotypes. Circ Arrhythm Electrophysiol:711–718
Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G (1990) Overflow of catecholamine neurotransmitters to the circulation: source, fate and functions. Physiol Rev 70:963–985
Hasking G, Esler M, Jennings G, Burton D, Johns J, Korner P (1986) Norepinephrine spillover to plasma in congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73:615–621
Adanich R, El Hunjut M, Alkhawam H, Kosmas CE, Madanich A, Vittorio TJ (2016) A perspective on sympathetic renal denervation in chronic congestive heart failure. Heart Fail Rev 21:1–10
Afari ME, Syed W, Tsao L (2018) Implantable devices for heart failure monitoring and therapy. Heart Fail Rev 23:935–944
Kingwell BA, Thompsom JH, Kaye DM, Mc Pherson GA, Jennings GL, Esler MD (1994) Heart rate spectral analysis, cardiac norepinephrine spillover and muscle sympathetic nerve activity during human sympathetic nervous activation and failure. Circulation 90:234–240
Allman KC, Wieland DM, Muzik O, Degrado TR, Wolfe ER, Schwaiger M (1993) Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J Am Coll Cardiol 22:368–375
Goldstein DS, Holmes C, Cannon RO III, Eisenhofer G, Kopin IJ (1997) Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 336:696–702
Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, Esler MD (1996) Cardiac sympathetic nerve function in congestive heart failure. Circulation 93:1667–1676
Goldstein DS, Holmes C, Stuhlmuller JE, Lenders GW, Kopin IJ (1997) 6-[18F] fluorodopamine positron emission tomography (PET) scanning in the assessment of cardiac sympathoneuronal function. Clin Auton Res 7:17–29
Chidsey CA, Braunwald E, Morrow GA (1965) Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med 39:442–451
Chidsey CA, Braunwald E, Morrow GA, Mason DT (1963) Myocardial norepinephrine concentration in man: effects of reserpine and of congestive heart failure. N Engl J Med 269:653–658
Esler MD, Kaye D (2000) Measurement of sympathetic nervous system activity in heart failure. The role of norepinephrine kinetics. Heart Fail Rev 5:15–25
Thomas JA, Marks BH (1978) Plasma norepinephrine in congestive heart failure. Am J Cardiol 41:233–243
Grassi G, D’Arrigo G, Pisano A, Bolignano D, Mallamaci F, Dell’Oro R, Quarti-Trevano F, Seravalle G, Mancia G, Zoccali C (2019) Sympathetic neural overdrive in congestive heart failure and its correlates: systematic reviews and meta-analysis. J Hypertens 37:1746–1756
Leimbach WN, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL (1986) Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 73:913–919
Grassi G, Seravalle G, Bertinieri G, Turri C, Stella ML, Scopelliti F, Mancia G (2001) Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomiopathy. Clin Sci 101:141–146
Grassi G, Seravalle G, Dell’Oro R, Facchini A, Ilardo V, Mancia G (2004) Sympathetic and baroreflex function in hypertensive or heart failure patients with ventricular arrhythmias. J Hypertens 22:1747–1753
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzales-Juanatey JR, Hariola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope M, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 37:2129–2200
Seravalle G, Quarti-Trevano F, Dell’Oro R, Gronda E, Spaziani D, Facchetti R, Cuspidi C, Mancia G, Grassi G (2019) Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction. J Hypertens 37:443–448
Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sagerman WS, Liuie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307:205–211
Nakata T, Hashimoto A, Sugawara H (2013) Cardiac metaiodobenzylguanidine imaging and heart failure. Curr Heart Fail Rep 10:359–364
Morris MJ, Cox HS, Lambert GW, Kaye DM, Jennings GL, Meredith IT, Esler MD (1997) Region-specific plasma NPY concentrations and overflows at rest and during sympathetic activation in man. Hypertension 29:137–143
Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM (2001) Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 22:1136–1143
Zucher IH, Liu JL (2000) Angiotensin II-nitric oxide interactions in the control of sympathetic outflow in heart failure. Heart Fail Rev 5:27–43
Singh RB, Hristova K, Fedacko J, El-Killary G, Cornelissen G (2019) Chronic heart failure. A disease of the brain. Heart Fail Rev 24:301–330
Eckberg DL, Drabinsky M, Braunwald E (1971) Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 285:877–883
Floras JS (2009) Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 54:375–385
Shivkumar K, Ajijola OA, Anand I, Armour JA, Chen PS, Elser MD, De Ferrari GM, Fishbein MC, Goldberger JJ, Harper RM, Joyner MJ, Khalsa SS, Kumar R, Lane R, Mahajan A, Po S, Schwartz PJ, Somers VK, Valderrabano M, Vaseghi M, Zipes DP (2016) Clinical neurocardiology - defining the value of neuroscience-based cardiovascular therapeutics. J Physiol 594:3911–3954
Cohn J, Levine T, Olivari MT, Garberg V, Tura D, Francis GS, Simon AB, Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with congestive heart failure. N Engl J Med 311:819–823
Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD (1995) Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26:1257–1263
Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FC, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS (2002) Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105:1354–1359
Barretto AC, Santos AC, Munhoz R, Rondon MU, Franco FG, Trobetta IC, Roveda F, De Matos LN, Braga AM, Middelekauff HR, Negrao CE (2009) Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int J Cardiol 135:302.307
Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B (2005) Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 26:906–913
DiBona GF, Kopp UC (1997) Neural control of renal function. Physiol Rev 77:75–197
Martins T, Vitorino M, Moreira-Goncalves D, Amado F, Duarte JA, Ferreira R (2014) Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia. Clin Biochem 47:8–15
Horwich TB, Fonarow GL, Clark AL (2018) Obesity and obesity paradox in heart failure. Prog Cardiovasc Dis 61:151–156
Esler MD, Lambert G, Schlaich M, Dixon J, Ika Sari C, Lambert E (2018) The obesity paradox in hypertension: is this due to the sympathetic nervous system activation in obesity-hypertension taking a benign form? Hypertension 71:22–33
Van Bilsen M, Patel HC, Bauersachs J, Böhm M, Borggrefe M, Brutsaert D, Coats AJS, de Boer RA, de Keulenaer GW, Filippatos GS, Floras J, Grassi G, Jankowska EA, Kornet L, Lunde IG, Maack C, Mahfoud F, Pollesello P, Ponikowski P, Ruschitzka F, Sabbah HN, Schultz HD, Seferovic P, Slart RHJA, Taggart P, Tocchetti CG, Van Laake LW, Zannad F, Heymans S, Lyon AR (2017) The autonomic nervous system as a therapeutic target in heart failure: a scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 19:1361–1378
Correale M, Monaco I, Tricarico L, Bottigliero D, Sicuranza M, Del Forno B, Godeas G, Teri A, Maiorano A, Perulli R, Centola A, De Bonis M, Di Biase M, Brunetti ND (2019) Advanced heart failure: non pharmacological approach. Heart Fail Rev 24:779–791
Jafri SM (2004) The effects of beta-blockers on morbidity and mortality in heart failure. Heart Fail Rev 9:115–121
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004
Devgun J, Jobanputra VB, Arustamyan M, Chait R, Ghumman W (2018) Devices and interventions for the prevention of the adverse outcome of tachycardia on heart failure. Heart Fail Rev 23:507–516
Hopper I, Gronda E, Hoppe UC, Rundqvist B, Marwick TH, Shetty S, Hayward C, Lambert T, Hering D, Esler M, Schlaich M, Walton A, Airoldi F, Brandt MC, Cohen SA, Reiters P, Krum H (2017) Sympathetic responses and outcomes following renal denervation in patients with chronic heart failure: 12-month outcomes from the Symplicity HF feasibility study. J Card Fail 23:702–707
Gronda E, Seravalle G, Brambilla G, Costantino G, Casini A, Alsheraei A, Lovett EG, Mancia G, Grassi G (2014) Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function and cardiac haemodynamics in heart failure. A proof-of-concept study. Eur J Heart Fail 16:977–983
Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Lovett EG, Muller-Ehmsen J, Scahfer J, Senni M, Swarup V, Wachter R, Little WC (2015) Baroreflex activation therapy for the treatment of heart failure with a preserved ejection fraction. J Am Coll Cardiol Heart Fail 3:487–496
Tsioufis C, Iliakis P, Kasiakogias A, Kostantinidis D, Lovic D, Petras D, Doumas M, Tsiamis E, Papademetriou V, Tousoulis D (2017) Non pharmacological modulation of the autonomic nervous system for heart failure treatment: where do we stand? Curr Vasc Pharmacol 16:30–43
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict(s) of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Grassi, G., Quarti-Trevano, F. & Esler, M.D. Sympathetic activation in congestive heart failure: an updated overview. Heart Fail Rev 26, 173–182 (2021). https://doi.org/10.1007/s10741-019-09901-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-019-09901-2